In summary, our primary study shows that insulin therapy can reduce the MCP-1 expression on the monocyte surface, serum MCP-1 level and NF-κB expression in monocyte, which indicates that short-term insulin intensive treatment can alleviate the increased micro-inflammatory state in T2DM patients. The gene discussed is CCL2; the disease is type 2 diabetes mellitus.